What is HLS Therapeutics Inc. (HLTRF) stock price today?

HLS Therapeutics Inc. (HLTRF) is currently trading at $2.98, up 0% today.

What is HLTRF P/E ratio?

HLS Therapeutics Inc.'s P/E ratio is -9.24. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is HLTRF return on equity (ROE)?

HLS Therapeutics Inc.'s return on equity (ROE) is -16.54%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is HLS Therapeutics Inc.'s market cap?

HLS Therapeutics Inc. has a market capitalization of $93.20M.

OTC · Drug Manufacturers - Specialty & Generic

HLS Therapeutics Inc. (HLTRF) Stock

$2.98 +0.00% OTC: HLTRF Healthcare

Valuation

Metric	Value
Price	$2.98
Market Cap	$93.20M
P/E Ratio	-9.24
P/B Ratio	1.59
P/S Ratio	1.67
EPS (TTM)	$-0.40
52-Week High	$4.02
52-Week Low	$2.98
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-16.54%
ROA	-7.82%
ROCE	-3.99%
Gross Margin	61.69%
Operating Margin	-7.34%
Net Margin	-18.42%
Debt/Equity	0.75
Current Ratio	1.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$60.0M	$61.0M	$63.0M	$57.0M	$56.0M
Operating Profit	$-6.0M	$-13.0M	$-10.0M	$-8.0M	$-4.0M
Net Profit	$-13.0M	$-24.0M	$-28.0M	$-20.0M	$-13.0M
EPS	$-0.41	$-0.73	$-0.85	$-0.62	$-0.40
Op Margin	-10.5%	-21.9%	-16.4%	-13.6%	-7.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$276.0M	$242.0M	$209.0M	$160.0M	$137.0M
Total Liabilities	$115.0M	$116.0M	$111.0M	$89.0M	$76.0M
Cash	$21.0M	$21.0M	$22.0M	$17.0M	$12.0M
Borrowings	$98.0M	$97.0M	$88.0M	$66.0M	$50.0M

Latest News

HLS Therapeutics to Host Q2 2026 Financial Results Conference Call CNW Group · Jul 29, 2026 HLS Therapeutics Reports Annual Meeting Results CNW Group · Jun 26, 2026 HLS Therapeutics to Begin its Normal Course Issuer Bid MT Newswires · Jun 23, 2026 HLS Therapeutics Announces Normal Course Issuer Bid CNW Group · Jun 23, 2026 HLS Therapeutics Q1 Earnings Call Highlights MarketBeat · May 16, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$16.0M	$17.0M	$16.0M	$8.0M	$16.0M
Investing Cash Flow	$-9.0M	$-30.0M	$0	$12.0M	$-2.0M
Financing Cash Flow	$5.0M	$-1.0M	$-3.0M	$-2.0M	$-2.0M
Net Cash Flow	$1.0M	$0	$1.0M	$-4.0M	$-6.0M
Free Cash Flow	$12.0M	$7.0M	$16.0M	$8.0M	$16.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.15
EV / EBITDA	7.02
FCF Yield	19.75%
Quick Ratio	0.75
Interest Coverage	-0.70
Return 1Y	-16.53%
Return 3Y	-37.26%
Return 5Y	-77.77%

Ownership

Insiders Held0.53%

Institutions Held43.95%

Institutions Float Held44.18%

Institutional Holder	Shares	Report Date
Canoe Financial LP	499,001	2023-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AMRXAmneal Pharmaceuticals, Inc.	$19.91	+1.32%	36.74	$6.36B	0.00%
AQSTAquestive Therapeutics, Inc.	$4.78	+0.42%	-7.11	$599.73M	0.00%
BHCBausch Health Companies Inc.	$6.04	+0.00%	-2.08	$2.26B	0.00%
CPHIChina Pharma Holdings, Inc.	$0.87	-9.32%	-0.65	$35.27M	0.00%
CPIXCumberland Pharmaceuticals Inc.	$7.03	+0.72%	-10.34	$105.33M	20.30%

About HLS Therapeutics Inc.

HLS Therapeutics Inc. is a specialized pharmaceutical firm engaged in the acquisition and commercialization of medicinal products, with a primary focus on the central nervous system (CNS) and cardiovascular (CV) therapeutic areas. The company's activities extend across Canada, the United States, and international territories. Its core product lineup features Clozaril, an atypical antipsychotic medication prescribed for schizophrenia; Vascepa, composed of icosapent ethyl capsules; and PERSERIS, an injectable risperidone formulation also employed in the treatment of schizophrenia. Beyond pharmaceuticals, HLS Therapeutics offers MyCare psychiatry laboratory assays and MyCare Insite point-of-care diagnostic tests for monitoring drug levels. Additionally, the company possesses U.S. marketing rights for Absorica, a commercially available dermatology product, along with Canadian rights for Trinomia, a cardiovascular therapeutic. It also benefits from royalty streams derived from four other healthcare products. HLS Therapeutics Inc. was founded in 2018 and maintains its headquarters in Etobicoke, Canada.

HLS Therapeutics Inc. is headquartered in CA.

HLS Therapeutics Inc. (HLTRF) stock trades at $2.98 with a market capitalization of $93.20M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.24, reflecting a net loss over the last twelve months, price-to-book of 1.59, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $2.98 and $4.02, and currently trades 25.9% below its 52-week high.

On profitability, HLS Therapeutics Inc. generates a return on equity (ROE) of -16.54% (negative, reflecting a net loss), return on capital employed of -3.99%, an operating margin of -7.34%, a net profit margin of -18.42%.

Official website: www.hlstherapeutics.com